Here are the 10-Q quarterly reports from InMed Pharmaceuticals Inc. (INM) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow INM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INM filings page.
InMed Pharmaceuticals Inc. (INM) reported a $2.33 million net loss for the three months ended September 30, 2026, versus $1.73 million a year earlier. Continuing-operations loss was $2.00 million; operating cash use was $1.14 million, versus $1.93 million. At quarter-end, cash and cash equivalents were $1.09 million, short-term investments $40,331, and shareholders’ equity a $1.20 million deficit. BayMedica had wound down InMed’s only revenue-generating commercial operations.
Management concluded substantial doubt exists about InMed’s ability to continue as a going concern within one year after the statements’ issuance. It expects $1.1 million of cash, cash equivalents and short-term investments as of September 30, 2026, to fund operating expenses and capital expenditures into calendar Q4 2026, depending on spending levels and timing.
The proposed merger with Mentari is expected to close in Q4 2026, subject to conditions including shareholder approvals and Mentari’s pre-closing financing. The financing commitment is approximately $490.0 million, including $50.0 million previously received. Assuming InMed net cash of approximately $(4.4) million at closing, Mentari holders and pre-merger InMed securityholders are expected to own 99.03% and 0.97%, respectively, of the combined company on a fully diluted basis, subject to adjustment. Nasdaq notified InMed that equity of $1,075,007 reported in its 2026 Annual Report was below the $2.5 million minimum; InMed submitted a plan.
InMed Pharmaceuticals Inc. reported lower commercial revenue and continuing losses for the three and six months ended December 31, 2025, while flagging substantial doubt about its ability to continue as a going concern. BayMedica’s rare‑cannabinoid business faces potential prohibition under new U.S. legislation, which could force inventory write‑offs or exit. The company also highlighted an arbitration over a technology license where the counterparty is seeking significant royalty payments, noting that an unfavorable outcome could materially harm its financial condition and BayMedica’s operations.
InMed Pharmaceuticals (INM) reported Q1 FY2026 results with Commercial segment sales of $1,120,121 versus $1,264,638 a year ago, reflecting lower pricing amid competition. Gross profit was $403,159 and the company recorded a net loss of $1,726,899 (basic and diluted EPS $(0.44)), compared with a net loss of $1,677,868 last year. Research and development expenses in the Pharma segment fell 17% to $575,458, while Commercial general and administrative costs rose 59% to $292,957.
Liquidity and balance sheet: Cash, cash equivalents and short‑term investments were $9,373,936 as of September 30, 2025, with cash and cash equivalents at $9,331,077. Total assets were $13,361,085, liabilities $1,770,462, and shareholders’ equity $11,590,623. Management states these resources are expected to fund operations into the fourth quarter of calendar 2026, yet concludes there is “substantial doubt” about continuing as a going concern. The quarter included the exercise of 602,000 pre-funded warrants, with an additional 200,000 exercised after quarter-end. Shares outstanding were 2,804,186 as of October 31, 2025.